About Akari Therapeutics (NASDAQ:AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKTX
CUSIPN/A
Phone44-20-8004-0270
Debt
Debt-to-Equity RatioN/A
Current Ratio3.19%
Quick Ratio2.38%
Price-To-Earnings
Trailing P/E Ratio-6.71
Forward P/E Ratio-1.02
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book1.11
Profitability
EPS (Most Recent Fiscal Year)($0.28)
Net Income$-32,570,000.00
Net MarginsN/A
Return on Equity-187.46%
Return on Assets-122.21%
Miscellaneous
Employees15
Outstanding Shares11,780,000
Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions
What is Akari Therapeutics' stock symbol?
Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."
How were Akari Therapeutics' earnings last quarter?
Akari Therapeutics (NASDAQ:AKTX) posted its earnings results on Wednesday, March, 21st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.59. View Akari Therapeutics' Earnings History.
When is Akari Therapeutics' next earnings date?
What price target have analysts set for AKTX?
4 brokerages have issued 1-year price objectives for Akari Therapeutics' shares. Their forecasts range from $2.50 to $8.00. On average, they anticipate Akari Therapeutics' stock price to reach $4.50 in the next year. View Analyst Ratings for Akari Therapeutics.
What are Wall Street analysts saying about Akari Therapeutics stock?
Here are some recent quotes from research analysts about Akari Therapeutics stock:
- 1. According to Zacks Investment Research, "Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. " (1/16/2018)
- 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: September 21, 2017, 23:12 ET Date and time of production: September 21, 2017, 20:41 ET Target Price / Valuation Methodology: Impax Laboratories – IPXL Our $19 price target is derived from a blend of DCF (7.7% WACC, +1% terminal growth) and a 9.2x forward EV/EBITDA on our 2018 estimates. IPXL shares currently trade around 8x our 2018 EV/EBITDA compared to a group average of around 9.2x. We think a group average EV/EBITDA valuation is warranted because of potential P&L leverage growing profitability faster than revenue which warrants a premium, a premium warranted for the company’s well-respected leadership offset by a discount to the group for relatively low expected top-line growth and a low-duration FTF/FTM based generics pipeline." (9/22/2017)
Who are some of Akari Therapeutics' key competitors?
Some companies that are related to Akari Therapeutics include Eleven Biotherapeutics (EBIO), BioLineRx (BLRX), Aralez Pharmaceuticals (ARLZ), Aileron Therapeutics (ALRN), Trillium Therapeutics (TRIL), Eyenovia (EYEN), KemPharm (KMPH), Advaxis (ADXS), Novan (NOVN), MEI Pharma (MEIP), Gemphire Therapeutics (GEMP), Oasmia Pharmaceutical (OASM), Cardiome Pharma (CRME), Medicure (MCUJF) and Alimera Sciences (ALIM).
Who are Akari Therapeutics' key executives?
Akari Therapeutics' management team includes the folowing people:
- Dr. Ray Prudo M.D., Exec. Chairman (Age 73)
- Mr. Dov Elefant, Chief Financial Officer (Age 51)
- Mr. Clive Richardson, COO & Director (Age 53)
- Dr. David Horn Solomon M.D., CEO & Director (Age 58)
- Dr. Miles Nunn, Chief Scientific Officer
Has Akari Therapeutics been receiving favorable news coverage?
News headlines about AKTX stock have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akari Therapeutics earned a news impact score of 0.14 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.49 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Akari Therapeutics?
Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akari Therapeutics' stock price today?
One share of AKTX stock can currently be purchased for approximately $1.89.
How big of a company is Akari Therapeutics?
Akari Therapeutics has a market capitalization of $23.08 million. The biopharmaceutical company earns $-32,570,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Akari Therapeutics employs 15 workers across the globe.
How can I contact Akari Therapeutics?
Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 44-20-8004-0270 or via email at [email protected]
MarketBeat Community Rating for Akari Therapeutics (AKTX)
MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics and other stocks. Vote "Outperform" if you believe AKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Akari Therapeutics (NASDAQ:AKTX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Akari Therapeutics in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 138.10%. The high price target for AKTX is $8.00 and the low price target for AKTX is $2.50. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.67 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.50 | $6.8333 | $8.75 | $8.75 |
| Price Target Upside: | 138.10% upside | 212.02% upside | 6.97% upside | 6.97% upside |
Akari Therapeutics (NASDAQ:AKTX) Consensus Price Target History
Akari Therapeutics (NASDAQ:AKTX) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Akari Therapeutics (NASDAQ:AKTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Akari Therapeutics (NASDAQ AKTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 61.80%
Institutional Ownership Percentage: 32.94%
Akari Therapeutics (NASDAQ AKTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/18/2015 | Mark S Cohen | Director | Buy | 1,055,600 | $0.19 | $200,564.00 | 1,055,600 |  |
| 4/15/2014 | Sabby Management, Llc | Major Shareholder | Buy | 20,100 | $5.03 | $101,103.00 | | |
| 4/11/2014 | Sabby Management, Llc | Major Shareholder | Buy | 2,575 | $5.35 | $13,776.25 | | |
| 4/8/2014 | Sabby Management, Llc | Major Shareholder | Buy | 68,404 | $5.59 | $382,378.36 | | |
| 4/2/2014 | Sabby Management, Llc | Major Shareholder | Buy | 28,207 | $6.22 | $175,447.54 | | |
| 3/27/2014 | Sabby Management, Llc | Major Shareholder | Buy | 16,203 | $6.66 | $107,911.98 | | |
| 3/24/2014 | Sabby Management, Llc | Major Shareholder | Buy | 11,100 | $6.83 | $75,813.00 | | |
(Data available from 1/1/2013 forward)
Akari Therapeutics (NASDAQ AKTX) News Headlines
| Source: |
|
Akari Therapeutics (NASDAQ:AKTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Akari Therapeutics (NASDAQ:AKTX) Income Statement, Balance Sheet and Cash Flow Statement
Akari Therapeutics (NASDAQ AKTX) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
